About Chimerix
Chimerix is a Healthcare company based in Durham (United Kingdom) founded in 2002, and was acquired by Jazz Pharmaceuticals in March 2025. Antiviral oral therapeutics are developed for infectious diseases and cancers. Chimerix has raised $95.23 million across 5 funding rounds from investors including Jazz Pharmaceuticals, New Leaf Venture Partners and Frazier Healthcare Partners. The company has 72 employees. Chimerix has completed 1 acquisition, including Oncoceutics. Chimerix offers products and services including TEMBEXA, ONC201, and ONC206. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics.
Company details
The company was founded in 2002 in Durham, United Kingdom, within the biotechnology sector. Antiviral oral therapeutics are developed, with a pipeline that includes Brincidofovir for smallpox treatment, ONC201 for mutant glioma, DSTAT for acute myeloid leukemia, and ONC206 for solid tumors. Quality of life is improved for patients across transplant, oncology, acute care, and global health settings through these operations.
- Headquarters Durham, United Kingdom
- Employees 72
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website chimerix.com
- Social LinkedIn X
- Acquired by Jazz Pharmaceuticals (Mar 2025)
- Annual Revenue$30 K (USD)-100as on Dec 31, 2023
- Net Profit-$88.39 M (USD)-8as on Dec 31, 2024
- EBITDA-$96.57 M (USD)-4as on Dec 31, 2024
- Total Equity Funding$95.23M (USD)
in 5 rounds
- Latest Funding Round$122M (USD), Post-IPO
Nov 2014
- InvestorsJazz Pharmaceuticals
& 9 more
- Employee Count72
- Investments & Acquisitions
- Acquired byJazz Pharmaceuticals
(Mar 2025)
Products & Services of Chimerix
Chimerix offers a comprehensive portfolio of products and services, including TEMBEXA, ONC201, and ONC206.
Treats serious viral diseases through targeted medication.
Addresses gliomas and brain tumors via innovative therapy.
Targets central nervous system tumors for improved outcomes.
Funding Insights of Chimerix
Chimerix has successfully raised a total of $95.23M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $122 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $95.23M
- Total Rounds 5
- Last Round Post-IPO — $122M
- First Round $11M
(Nov 2004)
- Investors Count 9
All 5 funding rounds of Chimerix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2014 | $122M | Post-IPO | – | – | – |
| Feb 2011 | $45M | Series F | – | New Leaf Venture Partners, Pappas Capital | |
| Jul 2009 | $16.13M | Series E | – | Alta Partners | |
| Feb 2007 | $23.1M | Series D | – | – | |
| Nov 2004 | $11M | Series C | – | – |
10 investors in total: 10 institutional.
Investors in Chimerix
Chimerix has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Jazz Pharmaceuticals, New Leaf Venture Partners and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
VC firm focusing on life science sector | pappas-capital.com | Durham, United States | ||
Canaan is recognized as an early-stage venture capital firm. | 1987 | canaan.com | San Francisco, United States | |
Biomedical investment financing and active management services. | sanderling.com | |||
Venture capital firm focused on healthcare companies | altapartners.com | Jackson, United States | ||
Early-stage US companies are invested in by Asset Management Ventures. | assetman.com | Palo Alto, United States | ||
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
US early-stage tech and life sciences companies are invested in. | fraziertechnology.com | Seattle, United States | ||
VC and private equity investments are made in China-US companies. | morningside.com.cn | Shanghai, China | ||
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | jazzpharma.com | Dublin, Ireland |
Investor details for Chimerix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Chimerix
43 people are tracked at Chimerix (24 in leadership, 5 in board & advisors, 14 in team); the tracked headcount is 72.
| Name | Role | Group |
|---|---|---|
Heather Knight-Trent | Vice President of Regulatory Affairs | Leadership |
Maggie Anderson | Clinical Development Manager, Associate Director Clinical Pharmacology | Leadership |
Allen Melemed | Chief Medical Officer | Leadership |
Mohammed Kabir | Executive Director Of Drug Product Manufacturing | Leadership |
Kana Cutchin | Associate Director, Lab Management | Leadership |
Rebecca Moraris | Senior Director, Clinical Operations | Leadership |
Sarah Godfrey (Corfman) | Project Director, Clinical Project Management | Leadership |
Stacy Jasper | Assoc Director, Regulatory Strategy And Clinical Development | Leadership |
Elizabeth M. | Associate Director, Clinical Operations | Leadership |
Odin Naderer | Vice President, Clinical Pharmacology and Translational Medicine | Leadership |
Rohinton Tarapore | Senior Director, Clinical Development | Leadership |
Andrea Armstead | Senior Director, Field Based Medical Affairs | Leadership |
Linda Azarbal | Director, Promotional Review & Commercial Operations | Leadership |
Mike Andriole | President & CEO | Leadership |
Michael A. Alrutz | Senior Vice President, General Counsel | Leadership |
Caryn Barnett | VP, Clinical Operations | Leadership |
Tom Riga | Chief Operating Officer And Chief Commercial Officer | Leadership |
Reyes O. | Associate Director Data Management | Leadership |
Aaron Downey | Director | Leadership |
Meghan Sullivan | Director Of Medical Affairs | Leadership |
23 more people are available in the full profile.
Complete people profiles for Chimerix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Chimerix
Chimerix has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Oncoceutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Clinical-stage drug development company focused on oncology | oncoceutics.com | Philadelphia, United States | 2009 | Jan 2021 | $78M |
Complete acquisition details for Chimerix
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Chimerix
6 dated milestones of Chimerix across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Chimerix is founded.
- Funding First funding round of $11.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $122.0M.
- Acquisition Acquires Oncoceutics.
- Exit Acquired by Jazz Pharmaceuticals.
Web traffic of Chimerix
The website of Chimerix (chimerix.com) receives about 1K visits a month and ranks #5,194,302 among all websites worldwide, #5,926 in Biotechnology and Pharmaceuticals.
- Monthly visits1K
▼ 70.1% vs previous month
- Unique visitors1.4K
per month
- Global rank#5,194,302
among all websites
- Category rank#5,926
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.6
- Average visit24 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with Chimerix. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| achaogen.com | 100% | View details | |||
| emergentbiosolutions.com | 99% | 35.6K | #745,411 | View details | |
| medreich.com | 99% | 1.9K | #7,047,446 | View details | |
| ardelyx.com | 98% | 17.8K | #2,305,983 | View details | |
| argostherapeutics.com | 95% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Chimerix
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Chimerix (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Chimerix
Complete news archive for Chimerix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Chimerix
Chimerix was founded in 2002 and raised its 1st funding round 2 years after it was founded.
Chimerix is headquartered in Durham, United Kingdom.
Chimerix is a funded company, having raised a total of $95.23M across 5 funding rounds to date. The company's 1st funding round was a Series C of $11M, raised on Nov 2004.
Chimerix has 72 employees.
Annual revenue of Chimerix is $30K as on Dec 31, 2023.
The company was founded in 2002 in Durham, United Kingdom, within the biotechnology sector. Antiviral oral therapeutics are developed, with a pipeline that includes Brincidofovir for smallpox treatment, ONC201 for mutant glioma, DSTAT for acute myeloid leukemia, and ONC206 for solid tumors. Quality of life is improved for patients across transplant, oncology, acute care, and global health settings through these operations.
Chimerix offers TEMBEXA, ONC201, and ONC206.
Chimerix has made 1 acquisition, including Oncoceutics.
Chimerix has 10 investors. Key investors include Jazz Pharmaceuticals, New Leaf Venture Partners, Frazier Healthcare Partners, Canaan, and Pappas Capital.
Yes. Chimerix was acquired by Jazz Pharmaceuticals in March 2025.